Compare Amgen, Inc. (AMGN) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Toyota Motor Corp — how do they compare? Amgen, Inc. trades at $362.06 (market cap $196.12B), while Toyota Motor Corp trades at $175.84 (market cap $206.62B). The key difference: Amgen, Inc. and Toyota Motor Corp are close in size by market cap, and Toyota Motor Corp pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| AMGN | TM | |
|---|---|---|
Market Cap | $196.12B | $206.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $248.29 |
52-Week Low | $271.18 | $166.50 |
Enterprise Value | $241.41B | $370.82B |
Dividend Yield | 2.77% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Toyota Motor (TM) trades at $176.45, up 1.22% today, with a neutral technical signal and strong fundamentals including a P/E of 9.67 and three consecutive quarterly EPS beats. The company announced a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling strategic U.S. investment. Revenue grew to $48.04T in 2025, though net income dipped slightly to $4.77T, while cash flow trends show projected recovery in 2026.
TM presents a value opportunity with low valuation multiples and consistent profitability, but faces risks from competitive pressures and fluctuating margins. Analyst consensus is mixed with 37.5% buy ratings, reflecting cautious optimism amid hybrid vehicle strength and macroeconomic uncertainties. The stock's outlook hinges on execution of expansion plans and sustained demand for fuel-efficient models.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
